Cargando…
In Vitro Evaluation of Recombinant Bone Morphogenetic Protein-2 Bioactivity for Regenerative Medicine
Recombinant human bone morphogenetic protein-2 (rhBMP-2) is a commonly used growth factor in bone regeneration due to its high potency and ability to induce osteogenic differentiation of osteoblasts and osteoblast precursors. When designing delivery systems for rhBMP-2, the activity of the loaded an...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761583/ https://www.ncbi.nlm.nih.gov/pubmed/31418333 http://dx.doi.org/10.1089/ten.tec.2019.0156 |
_version_ | 1783454052989796352 |
---|---|
author | Fung, Stephanie L. Wu, Xiaohuan Maceren, Julian P. Mao, Yong Kohn, Joachim |
author_facet | Fung, Stephanie L. Wu, Xiaohuan Maceren, Julian P. Mao, Yong Kohn, Joachim |
author_sort | Fung, Stephanie L. |
collection | PubMed |
description | Recombinant human bone morphogenetic protein-2 (rhBMP-2) is a commonly used growth factor in bone regeneration due to its high potency and ability to induce osteogenic differentiation of osteoblasts and osteoblast precursors. When designing delivery systems for rhBMP-2, the activity of the loaded and released protein is an important consideration. The variability in the experimental design parameters used to measure rhBMP-2 activity in vitro has precluded comparative analysis. Here, for the first time, we report a direct comparison of the assay parameters used in rhBMP-2 bioactivity assays in the literature and an evaluation of commercially available rhBMP-2 obtained from different vendors. Most published rhBMP-2 assays use W-20-17 (mouse stromal), MC3T3 (preosteoblast), or C2C12 (myoblast) cell lines. We found that each model cell line has an optimal concentration range over which it is most sensitive to rhBMP-2 induction. Therefore, it is difficult to find one single bioassay protocol that could be universally used. In addition, we established a correlation between protein concentration (as measured by enzyme-linked immunosorbent assay) and protein activity (as measured by alkaline phosphatase induction). We found that the expression system used to produce the rhBMP-2 had the greatest effect on its activity and stability in vitro. Establishing a standard method of measuring rhBMP-2 activity in vitro is the first step toward developing an in vitro–in vivo correlation between measured activity and clinical outcomes. IMPACT STATEMENT: This work is a systematic evaluation of the experimental parameters of the most widely used in vitro recombinant human bone morphogenetic protein-2 (rhBMP-2) activity assays. The variations in assays reported in the literature have challenged the reproducibility and translation of work using rhBMP-2 as a bone-inducing growth factor. By elucidating the effect of model cell line on the dose-dependent alkaline phosphatase response to rhBMP-2 induction and by establishing a correlation between protein activity and protein concentration by enzyme-linked immunosorbent assay using commercially available rhBMP-2, this work is a significant step toward developing an in vitro–in vivo correlation between quantified activity and clinical efficacy. |
format | Online Article Text |
id | pubmed-6761583 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Mary Ann Liebert, Inc., publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-67615832019-09-26 In Vitro Evaluation of Recombinant Bone Morphogenetic Protein-2 Bioactivity for Regenerative Medicine Fung, Stephanie L. Wu, Xiaohuan Maceren, Julian P. Mao, Yong Kohn, Joachim Tissue Eng Part C Methods Methods Articles Recombinant human bone morphogenetic protein-2 (rhBMP-2) is a commonly used growth factor in bone regeneration due to its high potency and ability to induce osteogenic differentiation of osteoblasts and osteoblast precursors. When designing delivery systems for rhBMP-2, the activity of the loaded and released protein is an important consideration. The variability in the experimental design parameters used to measure rhBMP-2 activity in vitro has precluded comparative analysis. Here, for the first time, we report a direct comparison of the assay parameters used in rhBMP-2 bioactivity assays in the literature and an evaluation of commercially available rhBMP-2 obtained from different vendors. Most published rhBMP-2 assays use W-20-17 (mouse stromal), MC3T3 (preosteoblast), or C2C12 (myoblast) cell lines. We found that each model cell line has an optimal concentration range over which it is most sensitive to rhBMP-2 induction. Therefore, it is difficult to find one single bioassay protocol that could be universally used. In addition, we established a correlation between protein concentration (as measured by enzyme-linked immunosorbent assay) and protein activity (as measured by alkaline phosphatase induction). We found that the expression system used to produce the rhBMP-2 had the greatest effect on its activity and stability in vitro. Establishing a standard method of measuring rhBMP-2 activity in vitro is the first step toward developing an in vitro–in vivo correlation between measured activity and clinical outcomes. IMPACT STATEMENT: This work is a systematic evaluation of the experimental parameters of the most widely used in vitro recombinant human bone morphogenetic protein-2 (rhBMP-2) activity assays. The variations in assays reported in the literature have challenged the reproducibility and translation of work using rhBMP-2 as a bone-inducing growth factor. By elucidating the effect of model cell line on the dose-dependent alkaline phosphatase response to rhBMP-2 induction and by establishing a correlation between protein activity and protein concentration by enzyme-linked immunosorbent assay using commercially available rhBMP-2, this work is a significant step toward developing an in vitro–in vivo correlation between quantified activity and clinical efficacy. Mary Ann Liebert, Inc., publishers 2019-09-01 2019-09-17 /pmc/articles/PMC6761583/ /pubmed/31418333 http://dx.doi.org/10.1089/ten.tec.2019.0156 Text en © Stephanie L. Fung et al., 2019; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Methods Articles Fung, Stephanie L. Wu, Xiaohuan Maceren, Julian P. Mao, Yong Kohn, Joachim In Vitro Evaluation of Recombinant Bone Morphogenetic Protein-2 Bioactivity for Regenerative Medicine |
title | In Vitro Evaluation of Recombinant Bone Morphogenetic Protein-2 Bioactivity for Regenerative Medicine |
title_full | In Vitro Evaluation of Recombinant Bone Morphogenetic Protein-2 Bioactivity for Regenerative Medicine |
title_fullStr | In Vitro Evaluation of Recombinant Bone Morphogenetic Protein-2 Bioactivity for Regenerative Medicine |
title_full_unstemmed | In Vitro Evaluation of Recombinant Bone Morphogenetic Protein-2 Bioactivity for Regenerative Medicine |
title_short | In Vitro Evaluation of Recombinant Bone Morphogenetic Protein-2 Bioactivity for Regenerative Medicine |
title_sort | in vitro evaluation of recombinant bone morphogenetic protein-2 bioactivity for regenerative medicine |
topic | Methods Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761583/ https://www.ncbi.nlm.nih.gov/pubmed/31418333 http://dx.doi.org/10.1089/ten.tec.2019.0156 |
work_keys_str_mv | AT fungstephaniel invitroevaluationofrecombinantbonemorphogeneticprotein2bioactivityforregenerativemedicine AT wuxiaohuan invitroevaluationofrecombinantbonemorphogeneticprotein2bioactivityforregenerativemedicine AT macerenjulianp invitroevaluationofrecombinantbonemorphogeneticprotein2bioactivityforregenerativemedicine AT maoyong invitroevaluationofrecombinantbonemorphogeneticprotein2bioactivityforregenerativemedicine AT kohnjoachim invitroevaluationofrecombinantbonemorphogeneticprotein2bioactivityforregenerativemedicine |